Thursday, April 25, 2019 11:22:19 PM
So that's the latest data. I don't consider that substantial in anyway, but that's just my opinion. It may seem like heavy shorting to others.
Mountain, molehill- potato patato.
Don't know if our familiar with the TLT ACT but it's a science that is being proven with excellent numbers and safety profile. If you look at the CR rates of TLT you can see the proven strength of the science.
They will be enrolling patients near term.
JMO, maybe, maybe not.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM